🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Myelodysplastic Syndrome
Clinical trial register · United States · industry-sponsored

Myelodysplastic Syndrome Trials in the USA

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9094 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
9094
Studies in scope
industry-sponsored, all four open statuses
4935
Recruiting now
open to new participants
2188
Lead sponsors
across recruiting studies
Top states
New York 6 California 5 Missouri 5 Florida 4 Massachusetts 3
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer1 Takeda1 Remedy Plan, Inc.1 Bristol-Myers Squibb1 Edgewood Oncology Inc.1
State
New York6 California5 Missouri5 Florida4 Massachusetts3
All 20 states
Target enrolment
to
9 of 9094 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
NCT07573111Acute Leukemia, Myelodysplastic Syndrome
Laguna Biotherapeutics, Inc.
Phase 1
12
California
2026-08
Recruiting
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT07422480Myelodysplastic Syndrome, Anemia
Takeda
Phase 3
300
Arizona, California, Florida, Georgia, Illinois, Kentucky, Missouri, New York
2026-05-21
Recruiting
Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
NCT07107126Acute Myeloid Leukemia, Myelodysplastic Syndrome
Remedy Plan, Inc.
Phase 1
24
New York, Texas
2026-02-13
Recruiting
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT06419634Acute Myeloid Leukemia, Myelodysplastic Syndrome
Bristol-Myers Squibb
Phase 1
105
Connecticut, Illinois, Massachusetts, Missouri, New Jersey, New York, Texas, Virginia
2024-05-29
Active, closed
Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test
NCT04635384Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
CareDx
Observational
307
California, Florida, Georgia, Massachusetts, Missouri, New York, Ohio, Oregon
2021-06-30
Active, closed
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
NCT04279847Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm
Incyte Corporation
Phase 1
140
Alabama, Colorado, Florida, Georgia, Iowa, Missouri, New Jersey, New York
2021-02-23
Active, closed
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
NCT04227847Myelodysplastic Syndrome, Acute Myeloid Leukemia
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
170
Alabama, California, Colorado, Kansas, Kentucky, Massachusetts, Michigan, Missouri
2020-08-07
Recruiting
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
NCT04243785Acute Myeloid Leukemia, Myelodysplastic Syndrome
Edgewood Oncology Inc.
Phase 1
80
California, New York, Texas
2020-01-06
Recruiting
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
NCT04167696Acute Myeloid Leukemia, Myelodysplastic Syndrome
Celyad Oncology SA
Phase 1
27
Florida, Kansas
2019-11-25
Rows per page Showing 1–9 of 9
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 September 2026. https://priyalifescience.com/clinical-trials-usa/condition/myelodysplastic-syndrome

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.